News & Events
- Seres Therapeutics to Participate in the Morgan Stanley 21st Annual Global Healthcare Conference
- Half-year report January–June 2023
- Genetic Analysis AS ramps up its market presence for the GA-map® microbiome testing in the US
- Genetic Analysis AS ramps up its market presence for the GA-map[®] microbiome testing in the US
- New publication shows the benefits of the GA-map® testing platform in Diabetes Type 2
- Seres Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Updates
- Seres Therapeutics to Host Second Quarter 2023 Financial Results and Operational Progress Conference Call and Webcast on August 8, 2023
- Seres Therapeutics to Present at Canaccord Genuity 43rd Annual Growth Conference
- MaaT Pharma Joins Microbiome Therapeutics Innovation Group
- Genetic Analysis receives patent approval in South Africa
- Seres Therapeutics Named to TIME100 Most Influential Companies List
- Seres Therapeutics and Nestlé Health Science Present Late-Breaking Data on VOWST™, a Microbiota-Based Oral Therapeutic for Prevention of Recurrence of C. Difficile Infection in Adults, at ASM Microbe 2023
- Seres Therapeutics to Present at Goldman Sachs Global Healthcare Conference
- Genetic Analysis AS enters an agreement with ELTA90 Group to distribute and launch GA-map® technology in the Balkan region
- Genetic Analysis AS enters an agreement with ELTA90 Group to distribute and launch GA-map[®] technology in the Balkan region